MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "L-threo-34-dihydroxyphenylserine(L-DOPS)"

  • 2019 International Congress

    Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson’s disease patients

    K. Hay, K. Mcdonell, P. Trujillo, M. Donahue, N. van Wouwe, D. Claassen (Nashville, TN, USA)

    Objective: To assess safety, tolerability, and central effects of L-Dihydroxyphenylserine (L-DOPS), in Parkinson’s disease (PD) patients treated with DOPA decarboxylase inhibition. Background: Norepinephrine (NE) is…
  • 2019 International Congress

    Changes in Supine Blood Pressure with Long Term Use of Droxidopa

    S. Gorny, L. Hewitt, A. Lindsten, M. Karnik-Henry, S. Kymes, A. Favit (Deerfield, IL, USA)

    Objective: To determine the long-term effects of droxidopa use on supine blood pressure (BP) in patients with neurogenic orthostatic hypotension (nOH). Background: nOH is a…
  • 2018 International Congress

    Droxidopa and Midodrine Treatment Persistence in Patients with Orthostatic Hypotension

    S. Kymes, K. Jackson, M. Widolff, C. Sullivan, L. Hewitt, S. Raj (Deerfield, IL, USA)

    Objective: To determine the treatment persistence of droxidopa and midodrine in patients with orthostatic hypotension (OH) or neurogenic orthostatic hypotension (nOH) when medication cost was…
  • 2017 International Congress

    Patient-Reported Outcomes in a Prospective Real-World Study of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension

    S. Kymes, C. François, K. McLeod, A. Duhig, A. Ogbonnaya, A. Quillen, J. Cannon, C. Shibao, B. Yue, I. Biaggioni (Deerfield, IL, USA)

    Objective: To assess the effect of droxidopa treatment on function, depression, and health-related quality of life (HRQoL) in patients with neurogenic orthostatic hypotension (nOH). Background:…
  • 2017 International Congress

    Effect of Droxidopa Treatment on Fear of Falling in Patients With Neurogenic Orthostatic Hypotension: Clinical Trial and “Real World” Results

    S. Kymes, C. François, G. Peng, G. Rowse, S. Isaacson (Deerfield, IL, USA)

    Objective: To assess the impact of droxidopa on fear of falling in patients with symptomatic neurogenic orthostatic hypotension (nOH) in 2 studies. Background: nOH results…
  • 2016 International Congress

    Systematic literature review of droxidopa in clinical trials for neurogenic orthostatic hypotension (nOH) in parkinsonism

    S. Tashiro, K. Dashtipour, J.J. Chen, K. Frei, E. Rashidian (Loma Linda, CA, USA)

    Objective: The aim of this study was to review the published evidence for the efficacy, safety, and dosing practices of droxidopa treatment for symptomatic neurogenic…
  • 2016 International Congress

    Impact of neurogenic orthostatic hypotension on healthcare utilization and costs associated with falls in Parkinson’s disease

    C. Francois, I. Biaggioni, C.A. Shibao, A. Ogbonnaya, H.C. Shih, E. Farrelly, A. Ziemann, A. Duhig (Deerfield, IL, USA)

    Objective: To compare demographic and clinical characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) and probable PD and neurogenic…

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley